MX351117B - Salt formulation of glycyrrhizic compounds in thermo reversible gel and trichloroacetic acid as a keratolytic topically applied in the genital tract in males and females with lesions caused by human papilloma virus infections as well as cancer therein. - Google Patents
Salt formulation of glycyrrhizic compounds in thermo reversible gel and trichloroacetic acid as a keratolytic topically applied in the genital tract in males and females with lesions caused by human papilloma virus infections as well as cancer therein.Info
- Publication number
- MX351117B MX351117B MX2011002098A MX2011002098A MX351117B MX 351117 B MX351117 B MX 351117B MX 2011002098 A MX2011002098 A MX 2011002098A MX 2011002098 A MX2011002098 A MX 2011002098A MX 351117 B MX351117 B MX 351117B
- Authority
- MX
- Mexico
- Prior art keywords
- glycyrrhizic
- cancer
- well
- papilloma virus
- human papilloma
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention refers to a novel formulation of ammonium salts of glycyrrhizic compounds such as glycyrrhizin, glycyrrhizic acid or glycyrrhetinic acid in a thermo reversible gel of the polyoxyethylene-polyoxypropylene-polyoxyethylene type as a vehicle at a 25% concentration, the compound being previously dissolved in propylene glycol as an absorption dissolvent or enhancer, at a compound concentration of from about 10, 20, 100mg/ml and to about 200 mg/ml of the active agent of the ammonium salts of glycyrrhizic acid; the compound includes a preserving agent such as methylparaben at a concentration of 0.1%, once the formulation is finished, the trichloroacetic acid being added at a cocnentration of 0.5 to 5.0% and finally the ph is maintained at a rate of 3-7, preferably at 3-5 due to physiological characteristics at a vaginal level. The invention is useful for the treatment of high and low grade intraepithelial squamous lesions related to Human Papilloma Virus recurrent infect ions of high and low oncogenic risk located at the inner and outer genital area such as cervix and vagina, and vulva, penis, anus, and rectum respectively, as well as cancer present in the aforementioned anatomic al regions in men and women.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2011002098A MX351117B (en) | 2011-02-25 | 2011-02-25 | Salt formulation of glycyrrhizic compounds in thermo reversible gel and trichloroacetic acid as a keratolytic topically applied in the genital tract in males and females with lesions caused by human papilloma virus infections as well as cancer therein. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2011002098A MX351117B (en) | 2011-02-25 | 2011-02-25 | Salt formulation of glycyrrhizic compounds in thermo reversible gel and trichloroacetic acid as a keratolytic topically applied in the genital tract in males and females with lesions caused by human papilloma virus infections as well as cancer therein. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011002098A MX2011002098A (en) | 2012-08-29 |
| MX351117B true MX351117B (en) | 2017-10-03 |
Family
ID=47225237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011002098A MX351117B (en) | 2011-02-25 | 2011-02-25 | Salt formulation of glycyrrhizic compounds in thermo reversible gel and trichloroacetic acid as a keratolytic topically applied in the genital tract in males and females with lesions caused by human papilloma virus infections as well as cancer therein. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX351117B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017010806A (en) * | 2017-08-22 | 2018-01-18 | Atso Corp Affairs S A De C V | Formulation of 18-beta-glicirretinic acid in combination with revesterol and metformin, uses and manufacturing method thereof. |
| MX2019009482A (en) * | 2019-08-08 | 2021-02-09 | Proyectos Atso S A P I De C V | PHARMACEUTICAL FORMS OF 18ß-GLICIRRETINICO ACID. |
| MX2021012629A (en) * | 2021-10-14 | 2023-04-17 | Maria Esther Dragustinovis Ruiz | Formulation for the management and antiviral, immunomodulatory, and anti-inflammatory treatment of the infection by the sars-cov2 virus (covid-19) and its variants formulated from the salt of glysirisinic acid and the derivates of its chemical structure, as well as antitussive and anthistaminic agents in syrup. |
-
2011
- 2011-02-25 MX MX2011002098A patent/MX351117B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011002098A (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1311259B1 (en) | Pharmaceutical composition comprising an ester of 5-aminolevulinic acid as photochemotherapeutic agent and a mucoadhesive agent | |
| US10130648B2 (en) | Therapeutic composition | |
| NZ596943A (en) | Semi-solid compositions and pharmaceutical products | |
| RU2013112666A (en) | PHARMACEUTICAL COMPOSITION | |
| JP2012529452A5 (en) | ||
| US10543228B2 (en) | Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas | |
| MX2011002098A (en) | Salt formulation of glycyrrhizic compounds in thermo reversible gel and trichloroacetic acid as a keratolytic topically applied in the genital tract in males and females with lesions caused by human papilloma virus infections as well as cancer therein. | |
| ES2227189T3 (en) | USE OF SUCRALFATE OR SUCROSA OCTASULFATE IN THE PREPARATION OF TOPIC INTRAVAGINAL MEDICINES FOR THE RESTORATION OF CERVICAL TISSUE. | |
| Fajdic et al. | Management of Fournier's Gangrene | |
| Patel et al. | Urinary bladder melanosis associated with urothelial dysplasia and invasive urothelial carcinoma | |
| ES2891148T3 (en) | Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder | |
| Md et al. | Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrophilic gel: a placebo-controlled double-blind study | |
| RU2445964C2 (en) | Method for eliminating atopobium vaginae bacteria in treating bacterial vaginosis | |
| ES2958808T3 (en) | Therapy of high-risk human papillomavirus infections | |
| US20120328530A1 (en) | Toluidine blue derivatives as photosensitising compounds | |
| Quint et al. | Vulvar disorders in adolescent patients | |
| RU2011134414A (en) | FULVIC ACID COMBINATION FOR TREATMENT OF VARIOUS CONDITIONS AND DISEASES | |
| ES2334746A1 (en) | Product for intimate hygiene based on red mirtillo and procedure for its preparation (Machine-translation by Google Translate, not legally binding) | |
| Lewis | Genital Dermatoses | |
| Khan | Chemotherapy of Genital Warts | |
| CHO et al. | Treatment efficacy of high dose progestin in young women with early stage of endometrial carcinoma | |
| EP3241555A1 (en) | Use of pyrophosphate ion analogues for the treatment of hpv infection | |
| Sidorova et al. | The effects of new pharmaceutical composition containing Epigallocatechin-3-Gallate (EGCG) to inhibit methylation of the tumor supressor genes in patients with cervical intraepithelial neoplasia | |
| Ekeruche-Makinde et al. | Exploring Innovative Approaches to the Formulation of Microbicides to Boost Antiretroviral Drug Delivery and Activity at Mucosal Sites | |
| Mohanty et al. | Nonvenereal male genital lesions: An update |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assignment |
Owner name: DESARROLLOS VPH, S.A. DE C.V. |
|
| FG | Grant or registration |